Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. Post author:Sam Post published:January 19, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017 FDA Expands Bristol-Myers Squibb’s Opdivo Dosing Schedule March 5, 2018 <b>Palleon Pharma</b> Bursts Onto the Scene With $47.6 Million and a New R&D Approach October 3, 2017
Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017
<b>Palleon Pharma</b> Bursts Onto the Scene With $47.6 Million and a New R&D Approach October 3, 2017